Selected stock price target news of the day - March 20th, 2025
By: Matthew Otto Five Below Beats Q4 Estimates but Issues Weaker-Than-Expected Full-Year Outlook Five Below reported fourth-quarter earnings per share of $3.48, exceeding analyst expectations of $3.37 by $0.11. Revenue for the quarter reached $1.39 billion, surpassing the consensus estimate of $1.38 billion. This represented a 4.0% year-over-year increase or 7.8% growth when excluding...
Read articleTrending topics
Selected stock price target news of the day - March 19th, 2025
By: Matthew Otto Trevi Therapeutics Reports Clinical Data and Financial Performance for 2024 Trevi Therapeutics has announced encouraging developments in its clinical programs targeting chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). The Phase 2a RIVER trial demonstrated that Haduvio™ achieved a statistically significant reduction in 24-hour cough frequency....
Read article
Selected stock price target news of the day - March 18th, 2025
By: Matthew Otto Belite Bio Reports Q4 and Full-Year 2024 Results, Updates on Phase 3 Trials and $15 Million Fundraising Belite Bio announced that the Data Safety Monitoring Board (DSMB) recommended the continuation of the Phase 3 DRAGON trial in adolescent Stargardt disease (STGD1) without modifications, with trial completion expected in Q4 2025. The...
Read article